Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 2/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.35 |
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086082 | 0.91 | NPC1 (0.36) | DNPH1NT5ECDK1P2RY12TMIGD3 | |
| SCHEMBL5086064 | 0.88 | TAS1R3 (0.38) | NT5EADORA2AADORA1ADORA2B | |
| SCHEMBL5083566 | 0.87 | TAS1R3 (0.42) | NT5EADORA2AADORA1ADORA2B | |
| SCHEMBL5083644 | 0.87 | ADORA1 (0.41) | NT5EADORA2AADORA1ADORA2B | |
| SCHEMBL5086004 | 0.85 | KDM4E (0.36) | NT5EADORA2ATYMP | |
| SCHEMBL5080069 | 0.81 | CDK1 (0.40) | CDK1TMIGD3ADORA2AADORA1ADORA2B | |
| SCHEMBL5083667 | 0.77 | P2RY1 (0.33) | DNPH1P2RY12ADORA1CDK2P2RX3 | |
| SCHEMBL5083620 | 0.75 | CCNB2 (0.39) | DNPH1NT5ECDK1TMIGD3ADORA2A | |
| SCHEMBL5080090 | 0.72 | RAB9A (0.40) | CDK1TMIGD3ADORA2AADORA1ADORA2B | |
| SCHEMBL5083000 | 0.69 | ADORA1 (0.41) | ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | DNPH1 566/4885NT5E 1175/4885CDK1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.